Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.

Int J Breast Cancer · 2015 · PMC4452841 · PMID 26078883

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

only marginally significantP = 0.057so close (0.05 < p ≤ 0.1)

Everolimus-based therapy was associated with numerically longer PFS than chemotherapy, although the difference was only marginally significant (log-rank test P = 0.057; unadjusted HR = 0.74, 95% CI: 0.55–1.01, P = 0.058; Table 2 ).

also in 5,085 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.